New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
November 25, 2009
15:26 EDTJNJ
theflyonthewall.com: Johnson & Johnson breaks out of reversed broadening formation
There was a reversed broadening formation on the weekly chart that had bearish implications had the bottom of the pattern been broken. The pattern began forming in mid-July. The breakout above the top of the pattern now has bullish implications. Upside potential for the pattern is to the $67 area. The $62.70 area is now key support for the shares, and the bullish pattern would be voided on a move back below this level. :theflyonthewall.com



News For JNJ From The Last 14 Days
Check below for free stories on JNJ the last two weeks.
There are 15 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 10, 2012
07:10 EDTJNJ
theflyonthewall.com: FDA outlines plan for biotech drug copies, WSJ reports

Subscribe for More Information
:theflyonthewall.com
06:18 EDTJNJ
theflyonthewall.com: On the Fly: Periodicals Wrap-Up

Subscribe for More Information
:theflyonthewall.com

February 9, 2012
16:27 EDTJNJ
theflyonthewall.com: Leerink's biotech and pharmaceuticals analysts hold a conference call
Biotech Analysts Schimmer and Liang, along with Pharmaceuticals Analyst Fernandez, review the reimbursement process for drugs in France on an Analyst/Industry conference call. Relevant covered companies ACOR, AMGN, AMLN, AUXL, BIIB, BMY, GILD, HGSI, ITMN, JNJ, NVS, PFE and VRTX may be included on the Analyst/Industry conference call to be held on February 10 at 11 am. :theflyonthewall.com

February 8, 2012
11:34 EDTJNJ
theflyonthewall.com: Watson reaches settlement with Janssen over generic Ortho Tri-Cyclen LO
Watson Pharmaceuticals (WPI) announced earlier that its subsidiary, Watson Laboratories, has reached a settlement with Janssen Pharmaceuticals (JNJ) on outstanding patent litigation related to Watson's generic version of Janssen's Ortho Tri-Cyclen LO tablets. As part of the settlement, the parties have entered into a supply agreement whereby Janssen will manufacture and supply Watson with an authorized generic version of Ortho Tri-Cyclen LO. Watson will have the right to market and distribute the authorized generic on December 31, 2015, or earlier under certain circumstances. Other details of the settlement were not disclosed. :theflyonthewall.com

February 7, 2012
10:33 EDTJNJ
theflyonthewall.com: Argus Research's healthcare analyst holds a conference call
Senior Healthcare Analyst Toung discusses healthcare and growth ideas for 2012 on an Analyst/Industry conference call. Relevant covered companies ABC, ABT, AET, BAX, BDX, BSX, CAH, CHSI, CI, ESRX, HMA, HOLX, HUM, IART, JNJ, MCK, MDT, MHS, STJ, SYK, UNH and ZMH may be included on the Analyst/Industry conference call to be held on February 8 at 11 am. :theflyonthewall.com

February 3, 2012
12:30 EDTJNJ
theflyonthewall.com: Johnson & Johnson sued in China over alleged price fixing, Shanghai Daily says

Subscribe for More Information
:theflyonthewall.com

February 2, 2012
14:15 EDTJNJ
theflyonthewall.com: da Vinci reimbursement set for April in Japan, says Collins Stewart
Collins Stewart confirmed with Intuitive Surgical (ISRG) management that the Japanese Ministry of Health indicated da Vinci prostatectomy is scheduled to be reimbursed beginning in April. The firm expects Intuitive Surgical, along with its Japanese partner Johnson and Johnson (JNJ), to pursue reimbursement for additional procedures. Collins Stewart says it is now more confident in Intuitive Surgical's long-term growth story and keeps a Buy rating on the stock. Note Lazard Capital said this morning in a note to investors that Japan is moving towards complete da Vinci prostatectomy reimbursement. :theflyonthewall.com
14:05 EDTJNJ
theflyonthewall.com: FDA and industry reach agreement in principle on medical device user fees
The FDA and representatives from the medical device industry have reached an agreement in principle on proposed recommendations for the third reauthorization of a medical device user fee program. The recommendations would authorize the FDA to collect $595M in user fees over five years, plus adjustments for inflation. Details of the agreement, such as the fee structure, are expected to be finalized soon. :theflyonthewall.com
10:19 EDTJNJ
theflyonthewall.com: On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Autoliv (ALV) downgraded to Sell from Buy at Citigroup...JDSU (JDSU) downgraded to Neutral from Buy at UBS...Vanguard Health (VHS) downgraded to Market Perform from Outperform at Wells Fargo...Steel Dynamics (STLD) downgraded to Neutral from Buy at BofA/Merrill...AK Steel (AKS) downgraded to Underperform from Neutral at BofA/Merrill...Northrop Grumman (NOC) downgraded to Underperform from Neutral at BofA/Merrill...Sykes Enterprises (SYKE) downgraded to Neutral from Outperform at RW Baird...NYSE Euronext (NYX) downgraded to Market Perform from Outperform at BMO Capital...QuinStreet (QNST) downgraded to Hold from Buy at ThinkEquity...Edwards Lifesciences (EW) downgraded to Neutral from Outperform at Credit Suisse...Ann Inc. (ANN) downgraded to Underweight from Neutral at Piper Jaffray...Johnson & Johnson (JNJ) downgraded to Market Perform from Outperform at First Global. :theflyonthewall.com
09:40 EDTJNJ
theflyonthewall.com: Johnson & Johnson downgraded to Market Perform from Outperform at First Global

Subscribe for More Information
:theflyonthewall.com
07:35 EDTJNJ
theflyonthewall.com: U.K. agency says it can't justify pricey J&J cancer drug, Bloomberg reports
In the U.K., Johnson & Johnson's (JNJ) prostate cancer medicine Zytig, discovered there and developed with funds from U.K. charities, is too expensive for the country’s National Health Service, reports Bloomberg. The National Institute for Health and Clinical Excellence said the NHS shouldn’t pay for the drug because its benefits don’t justify the cost even after J&J agreed to reduce the price. Reference Link :theflyonthewall.com

February 1, 2012
08:00 EDTJNJ
theflyonthewall.com: Medical device makers propose doubling of FDA fees, Bloomberg reports

Subscribe for More Information
:theflyonthewall.com

January 31, 2012
07:20 EDTJNJ
theflyonthewall.com: J&J changes McNeil unit leadership, WSJ reports
Johnson & Johnson (JNJ) is again shaking up its troubled McNeil Consumer Healthcare unit, replacing two company group chairmen, reports the Wall Street Journal. Reference Link :theflyonthewall.com
07:04 EDTJNJ
theflyonthewall.com: Johnson & Johnson option implied volatility low

Subscribe for More Information
:theflyonthewall.com

January 30, 2012
07:29 EDTJNJ
theflyonthewall.com: The FDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by Best Pharmaceuticals for Children Act and Pediatric Research Equity Act for Novartis Pharmaceuticals' Focalin XR, Shire's Daytrana, AstraZeneca's Seroquel and Atacand, Johnson & Johnson's Pancreaze, Eurand's Zenpep, Solvay Pharma's Creon, Meda Pharma's Xerese cream, Genentech's Xolair, Daiichi Sankyo's Benicar, Bayer's Mirena and Plan B One Step, and Boehringer Ingelheim's Flomax in a meeting to be held in Gaithersburg, Maryland on January 30 at 8 am. Webcast Link :theflyonthewall.com